This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.
Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding precision medicine in BRAF V600E–mutant metastatic colorectal cancer (CRC). Colorectal cancer is the second leading cause of cancer death among men and women in the United States, with the American Cancer Society estimating that there will be 106,970 new cases of colon cancer, 46,050 new cases of rectal cancer, and 52,550 deaths due to colorectal cancer in 2023 alon...
This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.
Oncology Data Advisor® · Harnessing Precision Medicine in Oncology With Ofer Sharon, MD In this interview, Ofer Sharon, MD, the CEO of OncoHost, explains the unique opportunities for harnessing precision medicine in oncology, the unmet needs regarding biomarker development, and the potential of utilizing a multicomponent biomarker approach for understanding the mechanisms of therapy resistance and developing novel pathways for treatment. Oncology Data Advisor: Welcome to Oncolo...
In this interview, Ofer Sharon, MD, the CEO of OncoHost, explains the unique opportunities for harnessing precision medicine in oncology, the unmet needs regarding biomarker development, and the potential of utilizing a multicomponent biomarker approach for understanding the mechanisms of therapy resistance and developing novel pathways for treatment.
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.
The old model of cancer treatments consisted of administering nonspecific cytotoxic therapies to various cancer patients. Now, cancer treatment has evolved to include agents that target a patient's genome and immune system, resulting in better patient outcomes. This 'precision medicine' approach individualizes treatment depending on each patient's unique tumor. Researchers discovered that using precision medicine to select combination treatments that target more than one genomic alteration is ef...